Stock Track | GRAIL, Inc. Soars 7.01% in Pre-Market on Optimistic Outlook for Cancer Screening and Robotaxi Prospects

Stock Track02-21

GRAIL, Inc. (GRAL) saw its stock surge 7.01% in the pre-market trading session on Friday, driven by an optimistic outlook from analysts regarding the company's prospects in the cancer screening and early detection market, as well as its robotaxi project.

Analysts are bullish on GRAIL's potential in the liquid biopsy market, with its Galleri multi-cancer early detection test showing promising results in clinical trials. The company's recent partnerships with leading healthcare providers have fueled expectations for widespread adoption and revenue growth.

Additionally, GRAIL's Apollo Go robotaxi project is expected to break even in Wuhan in 2024 and achieve profitability in 2025 as the company expands its fleet in the city. These positive developments, along with GRAIL's strong Q4 2024 earnings, with a 26% increase in revenue and successful integration with Quest Diagnostics, have contributed to the market's optimism and the pre-market surge in the company's stock.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1144662197?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-02-21 17:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144662197","market":"hk","top_or_hot":-1,"title":"Stock Track | GRAIL, Inc. Soars 7.01% in Pre-Market on Optimistic Outlook for Cancer Screening and Robotaxi Prospects","media":"Stock Track","content":"<p>GRAIL, Inc. (GRAL) saw its stock surge 7.01% in the pre-market trading session on Friday, driven by an optimistic outlook from analysts regarding the company's prospects in the cancer screening and early detection market, as well as its robotaxi project.</p>\n\n<p>Analysts are bullish on GRAIL's potential in the liquid biopsy market, with its Galleri multi-cancer early detection test showing promising results in clinical trials. The company's recent partnerships with leading healthcare providers have fueled expectations for widespread adoption and revenue growth.</p>\n\n<p>Additionally, GRAIL's Apollo Go robotaxi project is expected to break even in Wuhan in 2024 and achieve profitability in 2025 as the company expands its fleet in the city. These positive developments, along with GRAIL's strong Q4 2024 earnings, with a 26% increase in revenue and successful integration with Quest Diagnostics, have contributed to the market's optimism and the pre-market surge in the company's stock.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GRAIL, Inc. Soars 7.01% in Pre-Market on Optimistic Outlook for Cancer Screening and Robotaxi Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GRAIL, Inc. Soars 7.01% in Pre-Market on Optimistic Outlook for Cancer Screening and Robotaxi Prospects\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-21 17:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GRAIL, Inc. (GRAL) saw its stock surge 7.01% in the pre-market trading session on Friday, driven by an optimistic outlook from analysts regarding the company's prospects in the cancer screening and early detection market, as well as its robotaxi project.</p>\n\n<p>Analysts are bullish on GRAIL's potential in the liquid biopsy market, with its Galleri multi-cancer early detection test showing promising results in clinical trials. The company's recent partnerships with leading healthcare providers have fueled expectations for widespread adoption and revenue growth.</p>\n\n<p>Additionally, GRAIL's Apollo Go robotaxi project is expected to break even in Wuhan in 2024 and achieve profitability in 2025 as the company expands its fleet in the city. These positive developments, along with GRAIL's strong Q4 2024 earnings, with a 26% increase in revenue and successful integration with Quest Diagnostics, have contributed to the market's optimism and the pre-market surge in the company's stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GRAL","symbol_name":"GRAIL, Inc.","start_time":0,"source_url":"","article_id":"1144662197","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144662197","pubTimestamp":1740130351,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"GRAIL, Inc.  saw its stock surge 7.01% in the pre-market trading session on Friday, driven by an optimistic outlook from analysts regarding the company's prospects in the cancer screening and early detection market, as well as its robotaxi project.Analysts are bullish on GRAIL's potential in the liquid biopsy market, with its Galleri multi-cancer early detection test showing promising results in clinical trials. The company's recent partnerships with leading healthcare providers have fueled expe","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GRAL":"GRAIL, Inc."},"translate_title":"由于癌症筛查和机器人出租车前景乐观，GRAIL，Inc.盘前飙升7.01%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GRAL":1},"content_text":"GRAIL, Inc. (GRAL) saw its stock surge 7.01% in the pre-market trading session on Friday, driven by an optimistic outlook from analysts regarding the company's prospects in the cancer screening and early detection market, as well as its robotaxi project.\nAnalysts are bullish on GRAIL's potential in the liquid biopsy market, with its Galleri multi-cancer early detection test showing promising results in clinical trials. The company's recent partnerships with leading healthcare providers have fueled expectations for widespread adoption and revenue growth.\nAdditionally, GRAIL's Apollo Go robotaxi project is expected to break even in Wuhan in 2024 and achieve profitability in 2025 as the company expands its fleet in the city. These positive developments, along with GRAIL's strong Q4 2024 earnings, with a 26% increase in revenue and successful integration with Quest Diagnostics, have contributed to the market's optimism and the pre-market surge in the company's stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144662197"}